目的 探究奥拉西坦治疗脑梗死急性期的临床疗效。方法 选取2012年6月—2014年6月在天津市武清区人民医院接受治疗的脑梗死急性期患者200例, 随机分为对照组和治疗组, 每组100例。对照组采用常规方法治疗, 治疗组在对照组治疗的基础上静脉滴注奥拉西坦注射液, 4 g/次加入到250 mL生理盐水中。两组均连续治疗3周。治疗后, 观察两组的临床疗效, 同时比较两组治疗前后血管损伤因子抗心磷脂抗体(ACA)、高敏C反应蛋白(hsCRP)、同型半胱氨酸(Hcy)、NIHSS评分、Barthel指数的变化。结果 治疗后, 对照组和治疗组总有效率分别为79.0%、96.0%, 两组总有效率比较差异有统计学意义(P<0.05)。治疗后, 两组ACA、hsCRP、Hcy、NIHSS评分均较同组治疗前显著降低, Barthel指数显著升高, 同组治疗前后差异具有统计学意义(P<0.05);且治疗组这些观察指标的改善程度优于对照组, 两组比较差异有统计学意义(P<0.05)。结论 奥拉西坦治疗脑梗死急性期具有较好的临床疗效, 可降低神经功能损伤和血管损伤因子的相关指标, 同时还可提高患者的Barthel指数, 在临床具有一定的推广应用价值。

Objective To explore the efficacy of oxiracetam in treatment of cerebral infarction in acute phase. Methods Patients (200 cases) with cerebral infarction in acute phase in the People's Hospital of Wuqing from June 2012 to June 2014 were randomly divided into control and treatment groups, and each group had 100 cases. The patients in the control group were given conventional treatment. The patients in the treatment group were iv administered with Oxiracetam Injection, 4.0 g/time adding into physiological saline 250 mL. Two groups were treated for 3 weeks. After treatment, the efficacy was evaluated, and the changes of ACA, hsCRP, Hcy, NIHSS scores, and Barthel Index in two groups were compared. Results The efficacies in the control and treatment groups were 79.0% and 96.0%, respectively, and there were differences between two groups (P < 0.05). After treatment, ACA, hsCRP, Hcy, and NIHSS scores were significantly reduced, and Barthel Index were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment group improved better than those in the control group, with significant differences between two groups (P < 0.05). Conclusions Oxiracetam has good clinical efficacy in treatment of cerebral infarction in acute phase, and can reduce nerve function damage and related indexes of blood vessel damage, while can improve Barthel Index, which has certain application value in clinical.